Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

CD38 inhibition as a potent new therapeutic approach against ischemic brain injury

April 6, 2021

Vazkepa approved in E.U. to reduce cardiovascular risk in adults with elevated triglycerides

March 30, 2021

Cholesterol-independent heart disease risk gene

March 29, 2021

Heartseed to initiate phase I/II LAPiS study of iPSC-derived cardiomyocyte spheroids

March 26, 2021

Microvesicles promote infarct recovery in primates

March 25, 2021

ARTham Therapeutics provides first phase I data for ART-001 in healthy volunteers

March 22, 2021

FDA approves Arcalyst for recurrent pericarditis

March 19, 2021

Hefei Institutes of Physical Sciences presents new PDGFR-alpha and/or PDGFR-beta inhibitors

March 18, 2021

Injectable hydrogel with MSN/microRNA-21-5p complexes reduces infarct size in vivo

March 11, 2021

SBI and University of Oxford initiate phase II study of cardioprotective agent using 5-ALA

March 9, 2021

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...